NEW YORK, Oct. 31, 2015 /PRNewswire/ -- S1 Biopharma, Inc., a leading developer of first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women and men, today announced that Robert Pyke, MD, PhD, chief medical officer at S1 Biopharma, will present at the ExL Pharma CNS Clinical Trial Forum on Monday, November 2, 2015 at 10:30 AM at the Hyatt Regency Bethesda in Bethesda, Maryland.
Dr. Pyke's presentation, entitled "Identify Challenges for Getting CNS Combination Therapies Through Clinical Trials," will feature a case study review of the unique hurdles in development of combination therapies. He will outline the distinct regulatory pathways associated with combination therapy development and the special considerations in key areas including dosing evaluation.
About S1 Biopharma, Inc.
S1 Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of sexual dysfunction in both women and men. The company's development programs include first-in-class non-hormonal therapies designed to treat diminished sexual desire by restoring the natural balance of key neurotransmitters in the brain. The company's lead product candidate, Lorexys, is currently in a Phase 2a clinical trial for the treatment of hypoactive sexual desire disorder (HSDD) in women. S1 Biopharma is evaluating partnerships, collaborations and out-licensing deals that will enable the company to rapidly advance its sexual dysfunction franchise as well as to accelerate the path to commercialization for its drug candidates in the U.S. and internationally. For more information, visit http://s1biopharma.com/ or follow S1 Biopharma on Facebook or Twitter (@s1biopharma).
S1 Biopharma, Inc.
7 World Trade Center
250 Greenwich St., 46th Floor
New York City, NY 10007
Berry & Company Public Relations
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dr-robert-pyke-from-s1-biopharma-to-present-at-exl-pharma-cns-clinical-trial-forum-300169884.html
SOURCE S1 Biopharma, Inc.